S
everal lines of evidence suggest that T cell-based adoptive immunotherapy forms an attractive approach for the treatment of various malignancies. Infusion of donor lymphocytes for the treatment of hematological malignancies has been shown to result in 20 -80% complete remissions depending on the nature of the leukemia (1) (2) (3) (4) (5) . Successful adoptive immunotherapy based on adoptive transfer of ex vivo-expanded tumor infiltrating lymphocytes in conditioned recipients has been demonstrated for metastatic melanoma (6, 7) .
Although promising, the complex isolation methods of T cells with the desired Ag specificity and laborious and time-consuming tissue culture procedures are likely to prevent the widespread application of these approaches. We and others have demonstrated that these difficulties can be overcome by an alternative strategy, namely the transfer of T cell specificity by genetic introduction of TCR ␣-and ␤-chains into T lymphocytes (8 -15) . Because T cell specificity is exclusively determined by the TCR, genetic transfer of TCR chains to T cells generates T cells with the desired Ag specificity. The potential in vivo efficacy of TCR-transferred T cells has been demonstrated in mouse models (14 -17) . As shown in these various murine models, TCR-transferred T cells can be activated by Ag in vivo, home to effector sites, and can break tolerance against defined self Ags. Importantly, TCR gene transfer can largely halt tumor progression in a spontaneous prostate carcinoma model, under conditions in which vaccination is without effect (18) . Recently, in a clinical phase 1 study, autologous peripheral blood-derived lymphocytes transduced with a melanoma Ag recognized by T cells 1-specific TCR were reinfused in patients with metastatic melanoma after lymphodepleting chemotherapy (19) . Persistence of the TCR modified T cells was observed for Ͼ2 mo and two of fifteen patients showed objective tumor regression illustrating that, although optimization is required, TCR gene transfer is feasible in a clinical setting.
A potential complication in TCR gene transfer is the formation of mixed TCR dimers that occurs when introduced TCR ␣-and ␤-chains pair with the endogenous TCR ␣-and ␤-chains (20) . As the specificity of these mixed TCR dimers is unknown, the formation of unwanted autoreactivities cannot be excluded (12, 21) . Importantly, while no evidence for mixed dimer induced autoimmunity was observed in earlier murine experiments and a first phase I trial (14 -17, 19) , more recent data in mouse model systems indicate that under conditions of aggressive conditioning, severe mixed dimer-dependent autoimmune pathology can occur (G. Bendle, personal communication).
Prior work has illustrated that the ␥ and ␦ TCR chains that are expressed by ␥␦ T cells cannot form heterodimers with ␣ and ␤ TCR chains (22, 23) . We previously demonstrated that the redirection of ␥␦ T cells instead of ␣␤ T cells allows TCR gene transfer without the formation of mixed TCR dimers (24) . Specifically, in vitro experiments showed that after retroviral transfer of MHC class I-or MHC class II-restricted TCRs fully functional, redirected human ␥␦ effector cells were obtained capable of lysing leukemic cells in an Ag specific manner. TCR gene transfer into ␥␦ T cells requires either the cotransfer of the CD4 or CD8 coreceptor, or the use of coreceptor-independent TCRs, as the majority of ␥␦ T cells lack the expression of these coreceptors (25, 26) . However, as demonstrated previously, the joint introduction of TCR and coreceptor genes can be achieved readily (16, 24) .
A substantially greater concern is formed by the lack of information on the in vivo capacities of TCR-modified ␥␦ T cells. As compared with ␣␤ T cells, relatively little is known on the in vivo survival and effector functions of ␥␦ T cells. Furthermore, although ␥␦ T cells can be detected in peripheral blood and spleen, this T cell subset mainly resides in epithelial sites and this could affect the capacity of ␣␤ TCR-modified ␥␦ T cells to react to Ag (27) (28) (29) (30) (31) .
To address these issues, we investigated the in vivo function of ␣␤ TCR-modified ␥␦ T cells in a mouse model. Our data demonstrate that ␣␤ TCR gene transfer into ␥␦ T cells can be used as a safe method to generate functional Ag specific effector cells for adoptive immunotherapy. ϩ mice, splenocytes were stained with PE-conjugated anti-TCR␥␦ specific mAbs (BD Biosciences), anti-PE Microbeads (Miltenyi Biotec) were added and ␥␦ T cells were enriched by AutoMACS (Miltenyi Biotec) according to the manufacturer's protocol (Ͼ50% purity). Subsequently, the recovered cells were further purified using a FACSVantage (BD Biosciences) fluorescence-activated cell sorter. Purity of the thus obtained ␥␦ T cell population was Ͼ99%.
Materials and Methods

Mice and ␥␦ T cells
Construction of the retroviral vectors and production of the retroviral supernatant
The pMX vector encoding the TCR ␣-and TCR ␤ chains of the OT-I TCR separated by an internal ribosome entry site and the pMX vector encoding the murine CD8␣ and CD8␤ chains separated by an internal ribosome entry site have been described previously (16, 17) . Retroviral supernatants were obtained by transfection of Phoenix-E packaging cells with the indicated retroviral vectors in combination with pCLEco (33), using the Fu-GENE 6 transfection reagent (Roche Molecular Biochemicals). Retroviral supernatants were obtained 48 h after transfection and used for transduction of purified ␥␦ T cells.
Retroviral transfer of the OT-I ␣␤ TCR and coreceptors to ␥␦ T cells
Purified ␥␦ T cells were stimulated in 24-well plates for 24 h in RPMI 1640 medium (Life Technologies) supplemented with 8% FCS (BioWhittaker), penicillin (100 U/ml), and streptomycin (100 g/ml; Boehringer Mannheim) in the presence of irradiated autologous feeder cells, Con A (2 g/ ml; Calbiochem) and IL-7 (5 ng/ml; Santa Cruz Biotechnology).
Non-tissue culture-treated 24-well plates (Becton Dickinson) were coated with 0.5 ml of 30 g/ml recombinant human fibronectin fragment CH-296 (RetroNectin; Takara) at room temperature for 2 h. The CH-296 solution was removed and replaced with 0.5 ml of 2% BSA (SigmaAldrich) in PBS for 30 min at room temperature. The ␥␦ T cells were plated on RetroNectin coated plates (0.3 ϫ 10 6 cells/well) in 0.5 ml of retroviral supernatant and cultured at 37°C for 24 h. For in vivo assays, the cells were washed once in HBSS (Life Technologies), resuspended in HBSS, and injected in mice i.v. 
Influenza A and recombinant vaccinia virus
Flow cytometric analysis
For analysis of T cell responses, peripheral blood was drawn at the indicated time points. Erythrocytes were removed by incubation in erylysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA (pH 7.4)) on ice for 15 min. Cells were stained with the indicated Abs for 10 -15 min at room temperature. The following mAbs: anti-TCR␥␦ FITC, anti-TCR␥␦ PE, anti-TCRV␤5.1 FITC, anti-TCRV␣2 PE, anti-Ly5.1 PECy5, antiLy5.2 PECy5, and anti-CD8␣ allophycocyanin were obtained from BD Pharmingen, anti-CD8␤ PE was obtained from Caltag Laboratories. Before analysis, propidium iodide (1 g/ml; Sigma-Aldrich) was added to select for propidium iodide-negative (living) cells.
Intracellular IFN-␥ staining
For intracellular IFN-␥ staining, cells were incubated in the presence of either 0.1 g/ml OVA or 1 g/ml SV40 peptide for 4 h at 37°C, in the presence of GolgiPlug (1 l/ml; BD Biosciences). Subsequently, cells were surface stained with FITC-conjugated anti-Ly5.2 (BD Biosciences) and PE-conjugated anti-CD8␣ (Caltag Laboratories) mAbs for 15 min on ice. After washing, cells were incubated in Cytofix/ Cytoperm solution (BD Biosciences) for 20 min on ice, washed, and stained for intracellular IFN-␥ with allophycocyanin-conjugated anti-IFN-␥ mAb (BD Biosciences) on ice for 20 min.
In vivo cytotoxicity assay
Splenocytes were prepared from RIP-OVA high mice and divided into two groups. Cells were labeled with 0.5 or 5 mol/L CFSE (Molecular Probes) for 20 min at 37°C. Cells were washed, kept on ice, and subsequently the CFSE high cells were pulsed with 0.1 mol/L OVA 257-264 peptide for 1 h at 37°C. Five million cells from the CFSE low and the CFSE high peptide-pulsed cells were mixed together in equal proportions and injected i.v. into mice that had received ␥␦ T cells transduced with the OT-I TCR and CD8 coreceptor, and had been infected with either WSN-OVA or influenza A/HK/2/68. Spleens were removed 5 h later and single-cell suspensions were generated for FACS analysis. The percentage of target cell killing was determined as: 100 -((percentage of peptide-pulsed targets in WSN-OVA infected recipients/percentage of unpulsed targets in WSN-OVA infected recipients)/(percentage of peptide-pulsed targets in influenza A/HK/2/68 infected recipients/unpulsed targets in influenza A/HK/2/68 infected recipients) ϫ 100).
Results
Functional analysis of ␣␤TCR transduced ␥␦ T cells
To investigate the in vivo functionality of ␥␦ T cells that have been redirected by the introduction of an ␣␤ TCR, spleen derived ␥␦ T cells were isolated by immunomagnetic bead isolation and subsequent FACS sorting (Ͼ99% purity). Purified ␥␦ T cells were then stimulated with ConA and autologous irradiated feeder cells in the presence of IL-7, and after 24 h of stimulation retrovirally transduced with the OVA specific OT-I TCR. All TCR transductions were performed in combination with a retroviral vector encoding the CD8␣␤ coreceptor, as most ␥␦ T cells lack expression of this coreceptor. The OT-I CD8 transduced ␥␦ T cell population was infused i.v. (1 ϫ 10 5 cells per mouse), and the mice then received an intranasal infection with either a recombinant influenza A strain that expresses the OVA257-264 epitope (WSN-OVA) or a control influenza A strain (A/HK/2/68). Subsequently, the frequency of OT-I ϩ CD8 ϩ ␥␦ T cells in peripheral blood was determined by combined TCR␥␦, TCR V␣2, Ly5.2, and CD8 staining at various time points post infection. In mice that were infected with WSN-OVA a significant accumulation of the OT-I modified ␥␦ T cells was observed, with peak immune responses at day 9 post adoptive transfer (Fig. 1A, middle panels) . In contrast, in control mice that were infected with influenza A/HK/2/68 no significant numbers of OT-I modified ␥␦ T cells could be detected (Fig. 1A, top panel) . The TCR␥␦ ϩ TCR V␣2 ϩ CD8 ϩ cell population that was detected in mice infected with WSN-OVA expressed the Ly5.2 marker present on the donor cells, and was hence fully donor-derived. Furthermore, the vast majority of Ly5.2 ϩ cells present in these mice expressed the ␥␦ TCR, indicating that there was little if any contribution of the small amount (Ͻ1%) of cotransferred ␣␤ T cells (Fig. 1A, lower  panel) . These data demonstrate that ␥␦ T cells that are engineered to express an MHC class I-restricted TCR are capable of Ag-specific survival or proliferation upon interaction with Agexpressing APC in vivo.
To assess whether this Ag-driven activation of OT-I CD8 transduced ␥␦ T cells led to the acquisition of effector function, ␥␦ T cells from WSN-OVA and control influenza-infected mice were compared for their ability to produce IFN-␥ ex vivo. At the peak of the response (day 9), peripheral blood derived lymphocytes were stimulated either with OVA 257-264 peptide or SV40 large T 404 -411 control peptide. Subsequently, Ag-specific intracellular IFN-␥ production was determined by flow cytometry. A substantial fraction of Ly5.2 ϩ OT-I TCR transduced ␥␦ T cells that produced IFN-␥ was detected when lymphocytes derived from WSN-OVA-infected mice were stimulated with OVA but not when stimulated with the control Ag SV40 (Fig.  1B) . In addition, total splenocytes of A/HK/2/68-infected and WSN-OVA-infected mice were stimulated with OVA peptide and cultured for 14 days. Subsequently, the cultured splenocytes were restimulated with either SV40 or OVA peptide and intracellular IFN-␥ production was determined (Fig. 1C) . No Ly5.2 ϩ cells were detected in influenza A/HK/2/68 infected mice, indicating that efficient recovery of ␣␤ TCR transduced ␥␦ T cells requires in vivo Ag encounter. In contrast, substantial numbers of the adoptively transferred Ly5.2 ϩ OT-I CD8 transduced ␥␦ T cells were found in cultures from WSN-OVA infected mice and a large fraction of these cells produced IFN-␥ after stimulation with OVA peptide. Collectively, these data indicate that ␥␦ T cells modified with an ␣␤ TCR exhibit the potential to undergo Ag-driven expansion and display effector functions following in vivo activation.
Self-Ag-specific reactivity of ␣␤TCR transduced ␥␦ T cells
To investigate whether OT-I CD8 transduced ␥␦ T cells can expand upon Ag specific stimulation in a situation where the endogenous T cell repertoire is tolerant toward the OVA Ag, OT-I CD8 transduced ␥␦ T cells were infused in RIP-OVA high mice. In these FIGURE 1. Ag-specific expansion and cytokine production of ␥␦ T cells transduced with an ␣␤TCR. Purified ␥␦ T cells from Ly5.2 ϩ mice were transduced with the OT-I TCR in combination with CD8␣␤ and infused i.v. into Ly5.1 ϩ mice. Subsequently, the mice received an intranasal infection with either WSN-OVA or influenza A/HK/2/68. A, Representative FACS profiles at day 9 gated on CD8 ϩ cells from mice that received OT-I plus CD8 transduced ␥␦ T cells i.v. and which were subsequently infected with either influenza A/HK/2/68 (upper panels) (n ϭ 4) or WSN-OVA (middle panels) (n ϭ 4). In addition, flow cytometry profiles at day 9 are shown gated on Ly5.2 ϩ CD8 ϩ cells of the WSN-OVA infected mice (lower panel). B, Representative flow cytometry profiles of intracellular IFN-␥ staining of peripheral blood derived lymphocytes from Ly5.1 ϩ mice at the peak of the response (day 9) that received Ly5.2 ϩ OT-I plus CD8 transduced ␥␦ T cells, and were subsequently infected with either influenza A/HK/2/68 (data not shown) (n ϭ 4) or WSN-OVA (n ϭ 4). Peripheral blood-derived lymphocytes were ex vivo stimulated with the OVA 257-264 peptide or SV40 large T 404 -411 control peptide, and subsequently, Ag specific intracellular IFN-␥ production was determined by flow cytometry. C, Representative flow cytometry profiles of intracellular IFN-␥ staining of total splenocytes derived from Ly5.1 ϩ mice at the peak of the response (day 9) that received Ly5.2 ϩ OT-I ϩ CD8 transduced ␥␦ T cells, and were subsequently infected with either influenza A/HK/2/68 (n ϭ 4) or WSN-OVA (n ϭ 4). Splenocytes were in vitro stimulated with SV40 control peptide (data not shown) or OVA peptide, cultured for 14 days, restimulated with OVA or SV40 control peptide and, subsequently, Ag-specific intracellular IFN-␥ production was determined by flow cytometry. ␣␤TCR transduced ␥␦ T cells proliferated in vivo and produced cytokines upon Ag-specific stimulation. mice, OVA is expressed in pancreatic ␤ cells and no endogenous OVA-specific cytotoxic and helper T cell responses are observed (35, 36) . Following infusion of OT-I CD8 transduced ␥␦ T cells (5 ϫ 10 4 per mouse), the mice were infected either by intranasal application of influenza A/HK/2/68 or WSN-OVA, or by i.p. injection of a recombinant vaccinia virus expressing GFP-OVA 257-264 (rVV-OVA). At various time points, the percentage of OT-I CD8 transduced ␥␦ T cells in peripheral blood was monitored (Fig. 2) . In mice that received OT-I CD8-transduced ␥␦ T cells and were subsequently infected with either WSN-OVA or rVV-OVA, a substantial increase in ␣␤TCR transduced ␥␦ T cell number was observed, with a peak response of 8% of total CD8 ϩ T cells in the latter group. Similar to the kinetics observed upon Ag-induced proliferation of TCR-engineered ␣␤ T cells (14, 17), expansion was followed by a rapid contraction at the time of Ag clearance. As expected, no expansion of the V␣2 ϩ TCR␥␦ ϩ CD8 ϩ T cell population was observed in mice that were infected with influenza A/HK/2/68. Thus, ␣␤TCR-engineered ␥␦ T cells can respond to in vivo Ag encounter in a situation where the endogenous T cell repertoire is tolerant toward the Ag of interest.
Analysis of intestinal sites for the presence of ␣␤TCR-engineered ␥␦ T cells
A significant percentage of the CD8
ϩ lymphocytes present within the intestinal epithelium consists of ␥␦ T cells (27) (28) (29) (30) (31) . To investigate whether ␣␤TCR-transduced spleen-derived ␥␦ T cells would preferentially home to intestinal epithelial sites upon i.v. infusion, the number of ␣␤TCR transduced ␥␦ T cells in peripheral blood was compared with the number of ␣␤TCR-transduced ␥␦ T cells in the intra epithelial lymphocyte (IEL) 4 and lamina propriaresident (LP) lymphocyte fractions. RIP-OVA high mice received either OT-I CD8 transduced ␥␦ T cells, CD8 transduced ␥␦ T cells (2 ϫ 10 5 per mouse), or no T cells and were subsequently infected with WSN-OVA. As unmodified ␥␦ T cells lack expression of CD8␤ (26), expression of CD8␤ was used to distinguish endogenous and adoptively transferred ␥␦ T cells. The percentage of CD8␤ ϩ ␥␦ T cells in blood was monitored at various time points after the infection (Fig. 3A) . Only in peripheral blood of mice that received ␥␦ T cells transduced with the OT-I TCR in combination with the CD8 coreceptor CD8␤ ϩ ␥␦ T cells were detected. At the peak of the response (day 12) blood, IEL and LP lymphocyte fractions were analyzed by flow cytometric analysis. Although in peripheral blood percentages of total ␥␦ T cells up to 5% were observed, the percentage of total ␥␦ T cells in the IEL and LP reached levels up to 36 and 14%, respectively. In peripheral blood ϳ7.5% of the ␥␦ T cells consisted of OT-I CD8 transduced ␥␦ T cells (Fig. 3B) . Analysis of IEL and LP derived T cells of the mice that received either OT-I CD8 transduced ␥␦ T cells, or CD8 transduced ␥␦ T cells or no T cells showed that no significant numbers of OT-I CD8 transduced ␥␦ T cells could be detected in the intestine of the mice (Fig. 3C) . This indicates that the OT-I CD8 transduced ␥␦ T cells do not preferentially home to intestinal epithelial sites upon i.v. infusion.
In vivo persistence of ␣␤TCR-transduced ␥␦ T cells
To investigate whether infused OT-I CD8-transduced ␥␦ T cells are able to persist in vivo and have the capacity to mount a recall response RIP-OVA high mice received an i.v. infusion of OT-I CD8 transduced ␥␦ T cells (4 ϫ 10 5 ) and subsequently an intranasal infection with WSN-OVA or influenza A/HK/2/68. At various time points, the percentage of OT-I CD8 transduced ␥␦ T cells in blood was monitored. Mice that received OT-I CD8 transduced ␥␦ T cells and subsequently a WSN-OVA infection showed an increase in ␣␤TCR-transduced ␥␦ T cell number from day 7 with a peak of the response at day 10 and subsequent contraction (Fig. 4) . To test whether the Ag clearance preceding the observed contraction of the immune response was accompanied by cytolytic activity of the OT-I CD8 transduced ␥␦ T cells, an in vivo cytotoxicity experiment was performed. Influenza A/HK/2/68 or WSN-OVA infected RIP-OVA high mice infused with OT-I CD8 transduced ␥␦ T cells (4 ϫ 10 5 per mouse) received CFSE low labeled cells and OVA peptide pulsed CFSE high labeled cells i.v. The percentages of direct Ag specific target cell lysis of OVA peptide pulsed cells after 5 h varied from 18.5 to 24% (Fig. 5) . Thus, OT-I CD8 transduced ␥␦ T cells are capable of Ag specific cytolytic activity in vivo. To test in vivo persistence and the capacity of the OT-I CD8 transduced ␥␦ T cell to mount a recall response, the mice that initially received an WSN-OVA infection were challenged by i.p. injection of rVV-OVA after 12 wk. Upon rVV-OVA challenge a strong increase in the number of OT-I CD8 transduced ␥␦ T cells was observed in the peripheral blood of these mice leading to a recall response both in magnitude and kinetics comparable to the observed primary response (Fig. 4) . Thus, ␣␤TCR-modified ␥␦ T cells are capable of prolonged in vivo persistence and the ␣␤TCR modified ␥␦ T cells can mount recall responses.
Discussion
In the current study, we showed that ␥␦ T cells modified with an ␣␤TCR and the relevant coreceptor proliferated in vivo in an Ag specific manner, were able to persist in vivo and had the capacity to mount recall responses. The modified ␥␦ T cells were found to reside in peripheral blood, and only low numbers were detected in the intestinal epithelial sites. Functional analysis indicated that ␣␤TCR and CD8 transduced ␥␦ T cells produced IFN-␥ upon Ag specific stimulation directly ex vivo and after in vitro stimulation.
The currently most established strategy for TCR gene transfer, in which TCR genes are introduced into ␣␤ T cells results in the formation of mixed TCR dimers due to pairing of endogenous and introduced TCR␣ and TCR␤-chains (20) . The specificity of the mixed TCR dimers is unknown and may be harmful, and therefore avoidance of the formation of mixed TCR dimers is desired. We propose TCR gene transfer into ␥␦ T cells instead of ␣␤ T cells, 
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ϩ ␥␦ T cells in blood was analyzed. At 12 wk after the primary response the mice that initially received a WSN-OVA infection (n ϭ 3) were challenged with an intraperitoneal injection of rVV-OVA. Data represent group averages Ϯ SD. ␣␤TCR transduced ␥␦ T cells persisted in vivo and generated T cell memory. which prevents the formation of mixed TCR dimers because ␥␦TCR chains cannot pair with ␣␤TCR chains (22, 23) .
As compared with earlier experiments in which the in vivo function of TCR modified ␣␤T cells was investigated in murine models, TCR-modified ␥␦ T cells appear to have a somewhat lower proliferative capacity and in vivo effector function (17, 37) . This may in part be explained by the relatively low cell numbers used in this study. The ␥␦ T cells isolated from spleen tissue underwent a stringent sorting procedure to render a Ͼ99% pure population, which unfortunately decreased the number of cells available for infusion. Furthermore, this selection process may also have affected the viability of the ␥␦ T cells, reducing the proliferative capacity and therefore the effectiveness of the cells. This is in contrast to previous studies with TCR-transduced ␣␤ T cells, in which no sorting procedures were required (14, 17) . Importantly, it seems plausible that high numbers of TCR-modified ␥␦ T cells can be generated with substantially greater ease in the human setting (see below).
Conflicting data exist on the capacity of ␥␦ T cells to persist in vivo, to form long term immunological memory after an initial infection, and to subsequently mount a rapid recall response upon reinfection. Although some murine studies showed a lack of effective immunity of ␥␦ T cells to rechallenge (38 -41) , adoptive transfer of mouse ␥␦ T cell lines to naive recipients has been demonstrated to successfully restrict a malaria infection (42, 43) . Furthermore, in a nonhuman primate model, ␥␦ T cells showed a memory type response with rapid ␥␦ T cell expansion after a rechallenge, leading to clearance of detectable bacteremia (44) . Recently, long term expansion of ␥␦ T cells in CMV-seropositive individuals followed by quicker responses to rechallenge in graft recipients by ␥␦ T cells with an effector/memory phenotype was observed (45) . In the present study, mice that had initially undergone WSN-OVA infection showed a strong increase in the number of ␣␤TCR transduced ␥␦ T cells after rechallenge with rVV-OVA. The magnitude and kinetics of the secondary T cell response of the ␣␤TCR-transduced ␥␦ T cells were comparable to those observed in the primary response, indicating that ␣␤TCR transduced ␥␦ T cells are able to persist long-term in vivo and can mount recall responses.
For successful clinical application of ␣␤TCR engineered ␥␦ T cells some criteria have to be met. Sufficient numbers of ␥␦ T cells have to be available by easy isolation methods, isolated ␥␦ T cells must have the capacity not only to survive but also to proliferate in vitro and it must be possible to induce sufficient activation of the isolated ␥␦ T cells to enable retroviral transduction of the ␣␤TCR and the relevant coreceptor. Human ␥␦ T cells can be easily isolated from peripheral blood because percentages of ␥␦ T cells up to 10% of PBMC can be found (46, 47) . It has been shown possible to expand isolated ␥␦ T cells in vitro without deterioration of their effector functions (48) . Recently, two studies demonstrated the feasibility of clinical application of adoptive immunotherapy of unmodified ␥␦ T cells (49, 50) . Up to 8 ϫ 10 9 infused in vitro cultured ␥␦ T cells were well tolerated by patients and in vivo antitumor reactivity was observed. The feasibility of ␣␤TCR and coreceptor transfer to ␥␦ T cells was demonstrated in our previous study in which ␣␤TCR engineered ␥␦ T cells were found to proliferate vigorously in vitro, to produce cytokines in an Ag specific manner and to exert Ag specific cytotoxicity against leukemic cells (24) . These data together with the data from the present study provide evidence that ␥␦ T cells equipped with an ␣␤TCR can function specifically both in vitro and in vivo and that these effector cells may offer a safe alternative for the use of ␣␤ T cells in immunotherapy (19) .
In summary, we show in this study that ␣␤TCR transduced ␥␦ T cells proliferate in vivo and produce cytokines in an Ag-dependent fashion. In addition, these gene-modified ␥␦ T cells persisted in vivo and were capable of mounting recall responses. The combination of functional reactivity and lack of mixed dimer formation makes ␣␤TCR modified ␥␦ T cells an attractive cell population for future clinical studies.
